key: cord-0859258-4koml382
authors: Eslami, Solat; Glassy, Mark C; Ghafouri-Fard, Soudeh
title: A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients
date: 2021-12-09
journal: Gene
DOI: 10.1016/j.gene.2021.146113
sha: fa7041e98f6fc361fa8660a9733502f18d0e61e3
doc_id: 859258
cord_uid: 4koml382

Since late 2019, when SARS-CoV-2 was reported at Wuhan, several sequence analyses have been performed and SARS-CoV-2 genome sequences have been submitted in various databases. Moreover, the impact of these variants on infectivity and response to neutralizing antibodies has been assessed. In the present study, we retrieved a total number of 176 complete and high-quality S glycoprotein sequences of Iranian SARS-COV-2 in public database of the GISAID and GenBank from April 2020 up to May 2021. Then, we identified the number of variables, singleton and parsimony informative sites at both gene and protein levels and discussed the possible functional consequences of important mutations on the infectivity and response to neutralizing antibodies. Phylogenetic tree was constructed to represent the relationship between Iranian SARS-COV2 and variants of concern (VOC), variants of interest (VOI) and reference sequence. We found that the four current VOCs – Alpha, Beta, Gamma and Delta - are circulated in different regions in Iran. The Delta variant is notably more transmissible than other variants, and is expected to become a dominant variant. However, some of the Delta variants in Iran carry an additional mutation, namely E1202Q in the HR2 subdomain that might confer an advantage to viral/cell membrane fusion process. We also observed some more common mutations such as an N-terminal domain (NTD) deletion at position I210 and P863H in fusion peptide-heptad repeat 1 span region in Iranian SARS-COV-2. The reported mutations in the current project have practical significance in prediction of disease spread as well as design of vaccines and drugs.

Since December 2019, when the new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) was reported at Wuhan and quickly distributed all over the planet [1] , several sequence analyses have been performed and SARS-CoV-2 genome sequences have been submitted in various databases [2] . The Spike glycoprotein of this virus is a trimeric protein and each monomer comprises two functional subunits, S1 and S2 [3] . The S1 subunit is involved in the receptor recognition and mediates attachment to the host cell receptor, while S2 subunit participates in the fusion of the virus with the cellular membranes [4] . Mutations in SARS-CoV-2 spike-glycoprotein are of great interest as they mediate infection in human. Moreover, most of the approved vaccines are designed to induce immune responses against this protein [5] .

Therefore, continuous monitoring of SARS-CoV-2 spike-glycoprotein can provide valuable data, which can be helpful for early detection of variants that require adaptations in preventive and therapeutic strategies [5, 6] . They reported that S mutation D614G increases infectivity. While most of alterations in the receptor binding domain (RBD) reduce infectivity, A475V, L452R, V483A, and F490L variants induce resistance to some neutralizing antibodies [7] . More recently, Guruprasad has analyzed S protein sequences from almost all over the World and compared these sequences with the reference sequence from Wuhan-Hu-1. He has reported that about 80% of analyzed protein sequences contain at least one mutation. The observed mutations have been shown to occur in 400 distinctive mutation sites. Notably, 44 mutations have been reported in the RBD which participate in the interplays with the ACE2 receptor causing COVID-19 disease [8] . It is known that variation in the epitopes of SARS-CoV-2 RBD over time might introduce novel mutations which might challenge the development of broadly protecting antibodies and vaccines against SARS-CoV-2 [9] . These mutational variants might also lead to escape from the pre-existing cross-reactive CD4+ T cell responses or long-term protection from re-infection through T cell memory [10] . Hence, there is a necessity of constant monitoring of the rapidly changing mutation rates in the spike protein in SARS-CoV-2, which could have significant impact on virus infection, transmissibility and pathogenicity in the current pandemic [5] .

In the present study, we have retrieved sequences of S protein of SARS-CoV-2 viruses detected in Iran to identify notable mutations of S protein compared to the Wuhan isolate and representative sequences of variants of concern (VOC) and variants of interest (VOI). We also discuss the observed S protein mutations in terms of their distribution in different regions of Iran as well as sites and types of mutations. The reported mutations in the current project have practical significance in prediction of disease spread as well as development of vaccines and drugs.

Genetic variations of the S glycoprotein were identified in Iranian SARS-CoV-2 strains through the following steps. All SARS-CoV-2 sequences from Iran were obtained from the global initiative on sharing all influenza data (GISAID) and GenBank (National Center for Biotechnology Information, USA) submitted from April 2020 up to 24 May 2021. We also downloaded the representative sequences of S glycoproteins of VOC and VOI from GISAID for comparison with the S glycoproteins of Iranian SARS-COV-2. These sequences were subsequently aligned to the reference SARS-CoV-2 sequence (NC_045512). This step was accomplished using the MUSCLE program [11] implemented in Mega X [12] for amino acid or nucleotide sequences. The complete genome sequence of SARS-CoV-2 Wuhan-Hu-1 strain (NC_045512.2) was considered as the reference. The sequences that did not cover the entire S region were excluded. Furthermore, we excluded sequences that comprised the nucleotide ambiguity (N) and low-quality sequences. We used only one sequence for samples that have been repeated in both GenBank and GISAID. The final dataset included 176 complete and high-quality S glycoprotein sequences that were gathered during April 2020 until May 2021.

The complete SARS-CoV-2 S gene sequences were analyzed using the Molecular Evolutionary Genetics Analysis software (MEGA X) [12] . The aligned amino acid sequences were visualized.

Mutations were recognized through comparing the sequences with the reference SARS-CoV-2 sequence (NC_045512), which was regarded as the wild-type. Amino acids that were translated from codons comprising ambiguous bases (e.g. R, Y) were removed from mutation analyses.

The number of variables, singleton, and parsimony informative sites were tabulated at both gene and protein levels. After filtering the ambiguous data, the amino acid substitutions in S glycoprotein of all Iranian SARS-CoV-2 samples were determined. Residues that exhibited a mutation in at least 5 strains were considered as frequently mutated residues.

The acquired S gene sequences from Iranian SARS-COV-2 strains were aligned with representative S gene of SARS-CoV-2 sequences of the eleven recognized GISAID variants (4 VOCs and 7 VOIs) publicly available in the GISAID database and the Wuhan reference strain, (NC_045512) using MUSCLE multiple sequence alignment algorithms executed in MEGAX [11, 12] . For the purpose of simplicity, and to avoid clutter, of the 176 S gene sequences, only distinct S gene sequences (131 sequences) along with 11 sequences of VOC and VOI and one reference sequence were included for phylogenetic tree analysis. The evolutionary history was deduced by using the Maximum Likelihood method and Tamura-Nei model [13] . The tree topologies were supported by 1000 bootstrap replicates. The studied S gene of Iranian SARS-COV-2 was dispersed into many subbranches and some sequences were clustered in closer with the respective representative S gene of VOCs and reference sequence.

The viral clade distribution of Iranian SARS-COV-2 during the pandemic time were determined according to the information about Iranian SARS-CoV-2 complete genome sequences submitted in GISAID. A total number of 267 whole genome sequences of Iranian SARS-COV-2 has been deposited in public database of GISAID from April 2020 up to May 2021. However, some of these 267 SARS-COV-2 sequences had nucleotide ambiguity (N) and low-quality sequences in S gene sequences and some had identical S gene sequences. Thus, these sequences were excluded from mutation and phylogenetic tree analyses; however, the GISAID data of all of sequences were used for clades distribution analysis of SARS-CoV-2 in Iran. Dynamics and diversity of viral clades were identified during the pandemic time in Iran.

We retrieved a total number of 176 complete and high-quality S glycoprotein sequences of Wuhan-Hu-1(NC_045512.2) as reference. The complete length of the S glycoprotein sequences of human SARS-CoV-2 is 3822 nt, of which 450 variable sites were identified in 176 S glycoprotein sequences. Of these variable sites, 106 were parsimony informative, while 344 were singleton mutations. The results of nucleotide and protein alignment of SARS-CoV-2 S gene sampled from Iranian patients are shown in Table 1 . The identified mutations were distributed in different domains of spike protein with higher numbers of mutations being detected in NTD possibly resulting in escape from neutralizing antibodies. Figure 1 depicts the mutational profile of Iranian SARS-CoV-2 spike proteins. 

Next, we retrieved the most important mutations in signal peptide and N-terminal domain (NTD:

13-305aa), the number of events in Iranian spike protein sequences and assessed their possible functional implications based on the available reports in the literature (Table 3) . Similarly, mutations observed in RBD were assessed in terms of their implications in infectivity and clinical responses (Table 4 ). Moreover, we retrieved list of important mutations in RBD-Fusion peptide span region (Table 5) , and those within Fusion peptide domain, Fusion Peptide-Heptad repeat 1span region, Heptad repeat 1, Heptad repeat 1-Heptad repeat 2 span region and Heptad repeat 2 (Table 6) , as well as their clinical significance. Table 7) . Four of these nine sequences sampled from Yazd, in addition to indicator mutations of a Delta variant, also have a common E1202Q mutation in the HR2 subdomain, in which glutamine replaces glutamic acid at position 1202. We also found a total of seven sequences in Iran carrying all or some of specific mutations as indicator of Alpha variant. These sequences were reported from Shiraz, Tehran and Kerman (Table 9 ). Table  10 . Potential risks disrupt the epitope for mAb [20] reinforce the binding of the SARS-COV-2 spike with the hACE2 receptor increases viral replication in the upper respiratory tract and enhances the [30] vulnerability of the virus to neutralization by antibodies [37] There were two sequences carrying all of specific mutations as indicator of Beta variant. These sequences were reported from Hormozgan (Table 11 ). The Main characteristics of these SARS-CoV-2 variants are shown in Table 11 mutations as indicator of Gamma variant. Table 12 shows the main characteristics of the variant having specific mutations of a Gamma variant in Iran. Finally, main characteristics of the fifteen SARS-CoV-2 variants carrying A262T mutation in Iran are shown in Table 13 . 1st detection 03-2020 05-2020 04-2020 05-2020 04-2020 03-2020 03-2020 08-2020 03-2020 04-2020 04-2020 03-2020 04-2020 05-2020 2020-08

Other mutations in S  protein   T302A  D614G  R21K,  R44K,  D111N,  S112P   N542T,  V620F,  K77N  D614G   S459Y,  D614G   N487I,  V620I,  P225T,  D614G   D614G,  R328T   N536K,  T791P,  K811N,  T827A,   D843E,  N487H,  P1263L  T874P,  V987F,  Y144D,  Y200N   A672P,  C617R,  D287Y,  D586E,  E583A,  E661K,  G652R,  N603K,  N606Y,  T602K,  V289E   A1015,  A1026,  D843G,  K835N,  L841I,  P863H,  S1021P   K150I,  P863H,  Q675R,  V781F,  Y873N   D467N,  Q675R   Q498Y,  P499T,  T716P,  V11I,  L176F,  L179P  I726F   N487I,  N641K  V11I,  T22N,  Q23H,  H66L,  N74H,,   S758I,  P863H,  N925Y,  G932A,  D614G  Q115H,  V171L,  K182N,  T941P   D614G,  P412S,  P863H,  V407L and diversity of viral clades are shown during the pandemic time in Iran (Figure 3 ). There was a total number of 267 whole genome sequencing of Iranian SARS-COV-2 in public database of the GISAID from April 2020 up to May 2021. There was an initial period between February and June 2020 when the O clade (GISAID nomenclatures) was more prevalent in total than other clades (Figure 3b ). The clade O then slowly declined and almost disappeared in early November 2020, while the GISAID GH clade peaked at ca 65% in August and September 2020 and has slowly declined since December 2020.

The GISAID GR clade peaked at ca. 40% in October 2020 up to February 2021 and then rapidly declined. The GISAID GRY clade slowly increased from January 2021 and almost peaked at ca. The shared characteristic feature of these three clades is S_D614G mutation, which may increase the infectivity of SARS-CoV-2 [55] .

is also the main target of neutralizing antibodies; thus, it is evolving with a high speed. Besides, alterations in S protein explain at least a number of phenotypic variations expressed by VOC [15] . All VOCs (B.1.1.7, B.1.351, and P.1) and three B.1.617 sublineages have exhibited mutations inside and near the ACE2-interacting surface of S protein [15] .

We showed that the SARS-CoV-2 S protein contains tens of mutations in Iranian patients when compared to the initial SARS-CoV-2 sequence from Wuhan. These mutations are distributed in different domains of spike protein with higher numbers of mutations being detected in NTD, possibly resulting in escape from neutralizing antibodies. L452R, T478K, N501Y and S477N have been the most frequently detected mutations in RDB. Notably, N501Y and S477N has also been reported as frequent mutations in this domain in a World-wide assay [8] . Moreover, N501Y mutation is among mutations which are located at the boundary between the spike protein and ACE-2 receptor and can influence efficiency of vaccines and drugs targeted the interface of protein-protein interactions. In NTD, the most commonly detected mutations have been Del I210, EFR156-158G and T19R with the latter possibly disrupting the "super site" on the NTD [15] . Moreover, EFR156-158G has a role in immune evasion through antibody escape [22] . The D614G mutation as the only frequent mutation in the spike protein detected up to now among all the continents [8] , has been the most commonly detected mutation in RBD-Fusion peptide span region in Iranian samples.

Four of nine sequences sampled from Yazd, in addition to indicator mutations of a Delta variant, also have a common E1202Q mutation in the Heptad Repeat (HR2) subdomain, in which glutamine replaces glutamic acid at position 1202. The HR1 and HR2 domains are exposed to interact with each other to form a six-helical bundle (6-HB), consequently bringing viral and cellular membranes into close proximity to permit lipid bilayer fusion [56] . Therefore, mutations in HR1 and HR2 domains might affect heterologous 6-HBs forming, thus affecting viral/cell membrane fusion. Regarding the frequency of E1202Q mutation in Delta variant sequences from Iran, it seems that this mutation might confer an advantage to viral/cell membrane fusion process. One out of these four Delta variant sequence also showed a deletion in the NTD region of the spike protein at Y144. This Y144 deletion mutation is similar to the Y144 specific deletion mutation as indicator of the Alpha variant [57] , although up to the end of April 2021 this mutation has been reported in the 86

Delta variant sequences from different countries in GISAID Database. It has been shown that Y144 deletion contribute to immune escape and mostly confers resistance to most NTD-directed monoclonal antibodies (mAbs) [21] . We also observed an NTD deletion at position I210 in eleven sequences (6.3% of samples) sampled from May 2020 to January 2021 from four different cities. Ten out of these eleven sequences belonged to spike sequences carrying the mutation D614G (clade G); however, one sequence belonged to the Glade L, having the original amino acid aspartic acid at position 614.

The NTD of the virus spike protein has appeared as a potentially mutable structure. It has deletion-prone regions that may allow the virus to escape antibody neutralization [59] . We also observed triple co-occurring mutations, namely D138Y (in the NTD), S477N (in the RBD) with the well-established D614G mutation (near the furin cleavage site) in three spike sequences from Tehran and Shiraz sampled from Nov 2020 to Jan 2021. The mutations D138Y

and S477N are the same as those found in the NTD of VOC Gamma (P.1) and RBD of VOI of lota, respectively. It has been shown that these two mutations could contribute to reduced neutralization by some mAbs, convalescent plasma, and sera from vaccines. Moreover, they have higher binding affinity for human ACE2 [20, 30] . These co-occurring mutations might increase the concerns raised about these variants and needs to be further investigated for their public health impact and the possibility of becoming a VOC.

We also detected two complete SARS-COV2 genome sequences sampled from Hormozgan in There was another sequence sampled from Shiraz in Oct 2020 that contained five specific mutations (D138Y, D614G, E484K, K417T, N501Y) as indicator of the Gamma variant (GR/501Y.V3 (P.1+P.1.x)) and was clustered along with the representative Gamma variant spike sequence in phylogenetic tree. This sequence also had an additional mutation S477N in RBD.

The P.1 variant also has been raised particular concerns, including increased transmissibility, possible increased risk of hospitalization, moderate reduction in neutralizing activity of mAb and convalescent and post-vaccination sera [61, 23] . However, there are no other sequences of VOC Gamma variants from Iran, deposited in GISAID after Oct 2021 until Aug 2021.

We also found that the A262T mutation is the most frequent mutation (15 sequences; 8.5% of samples) among the Iranian SARS-COV2 spike sequences sampled from Mar 2020 to Aug 2020; however, this mutation has been disappeared after Aug 2020, probably due to the emergence of new variants. We found the mutation A262T in both spike sequence with the original D614 (8 out of 15) and with the well-established D614G mutation (7 out of 15). This mutation has been deposited in GISAID database in Mar 2020 for the first time from three countries including Iran, USA and Australia. Currently, the A262T mutation is seen in some variants from different countries with a very low frequency (221 SARS-COV2 sequences in GISAID).

We also assessed the distribution of SARS-COV-2 clades in Iran. This analysis determined the sequential prevalence of O, GH, GRY and G clades, the last one being characterized by D614G variant. We also suggested that currently more than 95% of the Iranian strains belong to the two major branches of the G clade, i.e., GR and GH clades and the newly introduced GRY clade. It is worth mentioning that differences in virulence of clades might at least partially explain differences in mortality rates or rate of transmission among different countries [55] . Consistent with this speculation, the comprehensive sequence analyses in each region have facilitated understanding the specific geographic distribution of SARS-CoV-2 variants. This information has practical significance in defining clinical and political strategies for management of this disorder in each geographic region.

Cumulatively, we reported the detected mutations in spike protein in Iranian SARS-CoV-2 samples. We found that the four current VOCs -Alpha, Beta, Gamma and Delta -are circulated in Iran. The Delta variant is notably more transmissible than other variants, and is expected to become a dominant variant. However, some of the Delta variants in Iran carry an additional mutation, E1202Q in the HR2 subdomain that might confer an advantage to viral/cell membrane fusion process. The mutations reported in the current study have importance in the development of antibody, vaccine, and drugs as well as designing management strategies for this disorder.

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in microbiology

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Human SARS CoV-2 spike protein mutations

SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors

MUSCLE: multiple sequence alignment with high accuracy and high throughput

MEGA X: molecular evolutionary genetics analysis across computing platforms

Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Molecular biology and evolution

CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention

Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum

Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70

SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine

Detection and characterization of the SARS-CoV-2 lineage B. 1.526 in New York. bioRxiv

Antibody evasion by the P. 1 strain of SARS-CoV-2. Cell

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell

E156G and Arg158, Phe-157/del mutation in NTD of spike protein in B. 1.617. 2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape. bioRxiv

Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization. Cell host & microbe

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Available at SSRN 3725763

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data

SARS-CoV-2 variant evades antibodies whilst maintaining fitness

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Vaccine-escape and fast-growing mutations in the United Kingdom, the United States

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. Scientific reports

Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe

SARS-CoV-2 variants, spike mutations and immune escape

Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination. medRxiv

Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? Viruses

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck

SARS-CoV-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations. Viruses

Characterization of the substitution hotspots in SARS-CoV-2 genome using BioAider and detection of a SR-rich region in N protein providing further evidence of its animal origin. bioRxiv

Detection of the recurrent substitution Q677H in the spike protein of SARS-CoV-2

SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. bioRxiv

Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B. 1.1. 7: role of the P681H mutation

SARS-CoV-2 evolution during treatment of chronic infection

D936Y and other mutations in the fusion core of the SARS-CoV-2 spike protein heptad repeat 1 undermine the post-fusion assembly

Natural infection of SARS-CoV-2 delta variant in Asiatic lions (Panthera leo persica) in India. bioRxiv

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Effectiveness of COVID-19 vaccines against the B. 1.617. 2 variant. medRxiv

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant

Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7. Nature

Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant501Y. V2. Centre for Mathematical Modelling of Infectious Diseases

Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma

Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Structural and Dynamical Differences in the Spike Protein RBD in the SARS-CoV-2 Variants B. 1.1. 7 and B. 1.351

The Delta Plus variant of COVID-19: Will it be the worst nightmare in the SARS-CoV-2 pandemic?

Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections. medRxiv

Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y. V2

Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab

Solat Eslami: Conceptualization, Methodology, Software Soudeh Ghafouri-Fard: Writing-Original draft preparation